98%
921
2 minutes
20
Vascular malformations are common vascular lesions in infants and seriously affect their health and quality of life. Vascular sclerotherapy is an effective treatment for vascular malformations. However, current sclerosants have difficulty achieving both high efficiency and low toxicity, and their dosing forms make it difficult to achieve long-term retention in the affected blood vessels. Therefore, exploring a safe and effective sclerosant and its delivery strategy is the key to clinical sclerotherapy. To address the above issues, this study developed sclerosants that could form an in-situ gel based on a dual mechanism of vascular injury and plasmin (PLA) inhibition. By linking the non-ionic surfactant sclerosant polyoxyethylene alkyl ether (PAs) and the PLA inhibitor tranexamic acid (TA) through an ester bond, a cationic surfactant sclerosant polyoxyethylene alkylether tranexamate derivatives (PATDs) were constructed. The cationic charge of PATDs enhanced its cytotoxicity to HUVEC-TIE2-L914F cells, and the ester bond of PATDs could be degraded by esterase in the blood, reducing its systemic toxicity. The degradation product TA inhibited the activation of the PLA-matrix metalloproteinase (MMPs) system induced by vascular injury, thereby promoting the deposition of collagen and the proliferation and differentiation of fibroblasts to promote vascular fibrosis. In addition, an injectable solution (PATDs/GA) was prepared by mixing PATDs with glycerol formaldehyde (GA), and PATDs/GA could form a low-molecular-weight gel automatically in an aqueous solution, which was beneficial to increase its retention in the affected blood vessels and reduce the risk of drug entering non-targeted sites. At the same time, this gel automatically dissolved, reducing the risk of immune rejection caused by long-term retention. This study provided a new and precise approach for the treatment of vascular sclerosis with high efficiency and low toxicity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653148 | PMC |
http://dx.doi.org/10.1016/j.mtbio.2024.101376 | DOI Listing |
Interv Neuroradiol
September 2025
J.J. Merland Department of Therapeutic Neuroangiography, University General Hospital of Catalonia and Hospital del Mar, Barcelona, Spain.
Background and purposeThis study presents our initial experience using Obtura, a novel nonadhesive liquid embolic agent with extra-low viscosity variants, in transvenous curative embolization of brain arteriovenous malformations (bAVMs). We assess the agent's performance and compare its advantages with other extra-low viscosity options currently available.Materials and methodsFive patients (three females, two males; mean age, 33 years; range, 20-55 years) with ruptured bAVMs were treated using the transvenous retrograde pressure cooker technique (TVRPCT).
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of Gastrointestinal Surgery, Jinhua Central Hospital, Jinhua, China.
Background: Chronic intestinal bleeding caused by vascular malformations is uncommon. Locating these small intestinal vascular malformations with precision during surgery remains a challenge. With the rapid development of digital subtraction angiography (DSA), the detection of small intestinal vascular malformations has become easier.
View Article and Find Full Text PDFCurr Gene Ther
August 2025
State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing 100191, China.
Cerebral Cavernous Malformations (CCMs) are vascular anomalies in the central nervous system that arise from both genetic and non-genetic factors, and can cause hemorrhage, seizures, and neurological deficits. Approximately 80% of CCMs are sporadic, while 20% are Familial (FCCMs), an autosomal dominant, monogenic disorder characterized by multiple lesions and severe clinical manifestations. Over the past three decades, linkage analyses have identified KRIT1/CCM1, MGC4607/CCM2, and PDCD10/CCM3 as major pathogenic genes in FCCMs.
View Article and Find Full Text PDFClin Nucl Med
September 2025
Departments of Nuclear Medicine.
This image highlights a diagnostic pitfall in a 65-year-old patient with recurrent glioblastoma. 18F-FET-PET revealed 2 hotspots with focally enhanced uptake: local tumor recurrence (TBRmax 2.3) on the left and another lesion in the right anterior cingulate gyrus (TBRmax 1.
View Article and Find Full Text PDFWorld Neurosurg
September 2025
Department of Neurosurgery, Medical University of South Carolina, Charleston, United States. Electronic address:
Background: Brainstem cavernous malformations (BSCMs) are rare yet high-risk vascular lesions with a complex clinical course due to their eloquent location. Optimal treatment remains a topic of debate. This review aims to evaluate the outcomes of different management strategies for BSCMs, with a focus on rebleeding, functional recovery, and mortality.
View Article and Find Full Text PDF